Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company’s Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Chief Executive Officer Brian Markis ...

Raises Revenue Guidance, Completes Medsphere Acquisition and Accelerates AI Initiative SOMERSET, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the quarter ended September 30, 2025, and is increasing its full-year 2025 revenue guidance to $117 – $119 million, up from the initial range of $111 – $114 million. CareCloud delivered another quarter of profitable growth, oper ...

Total Revenue of $223.6 million, up 122% Year-over-Year; Service Revenue of $190.0 million, up 132% Year-over-Year Net Loss of $1.9 million, which includes a $15 million pre-tax acquisition-related earn-out accrual Adjusted EBITDA(1) of $56.2 million, up 61% Year-over-Year Over 200 Year to Date shipments of Gogo's new cutting-edge Low Earth Orbit HDX antenna On track for year-end 2025 network launch of Gogo's new high-speed 5G Air-to-Ground (ATG) network All-time record of 437 ATG quarterly equipment shi ...

Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from AxsomeMIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“ ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced SUN SILVER LTD. (ASX: SS1; OTCQX: SSLVF), an Australian exploration company, has qualified to trade on the OTCQX® Best Market. SUN SILVER LTD. upgraded to OTCQX from the Pink® market. SUN SILVER LTD. begins trading today on OTCQX under the symbol “SSLVF.” U.S. investors can find current financial disclosure and Real-Time Level 2 ...

CALGARY, Alberta, Nov. 06, 2025 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) announced today that John Kousinioris, President and Chief Executive Officer and a Director of TransAlta, plans to retire effective April 30, 2026. Concurrent with this announcement, the Board of Directors (Board) has appointed Joel Hunter, TransAlta’s Executive Vice President, Finance and Chief Financial Officer, to succeed Mr. Kousinioris as President and Chief Executive Officer and b ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (‘Marex’ or the ‘Group’; Nasdaq: MRX) a diversified global financial services platform, providing essential liquidity, market access and infrastructure services to clients in the energy, commodities and financial markets, today reported financial results for the third quarter ('Q3 2025'). Ian Lowitt, Group Chief Executive Officer, stated, “I’m pleased to report strong third quarter financial results at the top end of our previously announced prelim ...

Raw Garden Live Resin Terpene Cartridges and All-in-One Vapes will be sold at Verano’s Four New Jersey Zen Leaf dispensaries and third-party retailers beginning November 11th. CHICAGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced an exclusive partnership with Raw Garden, a cultivator and producer of pure cannabis products balancing flavor and potency, to bring a suite of the Californ ...

End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net Loss Margin of 33.4%; Adjusted EBITDA1 of $43 million and Adjusted EBITDA Margin1 of 24.9% Narrowing 2025 Guidance to the higher end of previous ranges for Revenue and Adjusted EBITDA1 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“WeightWatchers,” “WW,” o ...

Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 inflammasome; initial readout including data from high-CVD risk cohort on track for H1 2026 VAV1-directed MGD MRT-61 ...